Piramal Pharma Limited (PPLPHARMA) — FY26 Annual Report | 3 July 2026(2 announcements)

Piramal Pharma Limited submitted its Business Responsibility & Sustainability Report for FY 2025-26 along with an Independent Auditor's Limited Assurance Report from DNV, forming part of its Annual Report. The filing covers statutory disclosures, corporate governance, sustainability initiatives, risk management, and compliance with ESG frameworks. It details environmental performance, employee welfare, stakeholder engagement, and adherence to regulatory standards, reflecting the company's commitment to responsible business practices and sustainable growth.

Piramal Pharma Limited's FY2026 annual report details its strategic focus on CDMO growth, sustainability, and governance amid financial headwinds. The company reported a consolidated net loss of ₹325.94 crores (down from ₹91.13 crores profit in FY2025) due to CDMO inventory destocking and softer inhalation sales, though revenue reached ₹8,869.08 crores. Key growth drivers include 48% US market share in Sevoflurane, acquisition of Kenalog® from BMS, and 48% e-commerce growth in Consumer Healthcare. Sustainability efforts show 22.6% GHG reduction, 40.9% renewable energy use, and 6,520 saplings planted. The board approved strategic investments ($90M in sterile injectables) and CDMO capacity expansion, while maintaining strong governance with 50% female directors and SEBI compliance. Dividend of [amount context mismatch] per share was recommended.